Latest filings (excl ownership)
8-K
Regulation FD Disclosure
20 May 24
8-K
Intelligent Bio Solutions Inc. Reports Fiscal 2024 Third Quarter and Nine-Month Financial Results and Operational Highlights
8 May 24
10-Q
2024 Q3
Quarterly report
8 May 24
8-K
Other Events
3 May 24
8-K
Results of Operations and Financial Condition
18 Apr 24
8-K
Regulation FD Disclosure
12 Apr 24
8-K
Regulation FD Disclosure
9 Apr 24
424B3
Prospectus supplement
28 Mar 24
EFFECT
Notice of effectiveness
28 Mar 24
D
$10.10 mm in equity / options, sold $10.10 mm, 8 investors
22 Mar 24
S-3
Shelf registration
18 Mar 24
424B3
Prospectus supplement
18 Mar 24
EFFECT
Notice of effectiveness
18 Mar 24
8-K
Intelligent Bio Solutions Announces $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules
12 Mar 24
S-3
Shelf registration
4 Mar 24
8-K
Entry into a Material Definitive Agreement
1 Mar 24
8-K
Intelligent Bio Solutions Partners with Cliantha Research to Conduct Clinical Study as Part of FDA 510(k) Pathway
29 Feb 24
8-K
Other Events
20 Feb 24
8-K
Intelligent Bio Solutions Inc. Reports Fiscal Second Quarter and Six-Month Financial Results and Operational Highlights
9 Feb 24
10-Q
2024 Q2
Quarterly report
9 Feb 24
8-K
Intelligent Bio Solutions Inc. Announces Exercise of Previously Issued Warrants for $1.77 Million in Gross Proceeds
7 Feb 24
8-K
Results of Operations and Financial Condition
2 Feb 24
8-K
Regulation FD Disclosure
30 Jan 24
8-K
Intelligent Bio Solutions Inc. Announces Reverse Stock Split
26 Jan 24
S-8
Registration of securities for employees
12 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4 Jan 24
8-K
Intelligent Bio Solutions Receives NATA Accreditation for its
21 Dec 23
8-K
Other Events
18 Dec 23
8-K
Submission of Matters to a Vote of Security Holders
14 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
17 Nov 23
DEF 14A
Definitive proxy
17 Nov 23
ARS
2023 FY
Annual report to shareholders
16 Nov 23
8-K
Intelligent Bio Solutions Inc. Reports Fiscal 2024 First Quarter Financial Results and Operational Highlights
8 Nov 23
10-Q
2024 Q1
Quarterly report
8 Nov 23
PRE 14A
Preliminary proxy
7 Nov 23
8-K
Departure of Directors or Certain Officers
6 Nov 23
DEF 14A
Definitive proxy
20 Oct 23
PRE 14A
Preliminary proxy
10 Oct 23
8-K
Intelligent Bio Solutions Adds Logistics Firm to Fingerprint Drug Screening Portfolio and Completes Major Milestone with Existing Client
5 Oct 23
8-K
Intelligent Bio Solutions Inc. Announces Pricing of $4,000,000 Underwritten Public Offering
4 Oct 23
Latest ownership filings
4
Spiro Kevin Sakiris
21 Mar 24
SC 13G/A
Ionic Ventures, LLC
14 Feb 24
SC 13G/A
Lind Global Fund II LP
13 Feb 24
SC 13G/A
Bigger Capital, LLC
5 Feb 24
SC 13G
Lind Global Fund II LP
20 Oct 23
SC 13G
Lind Global Fund II LP
10 Oct 23
4/A
Spiro Kevin Sakiris
10 Oct 23
4
CHRISTOPHER TOWERS
6 Oct 23
4
Spiro Kevin Sakiris
6 Oct 23
SC 13G
BIGGER CAPITAL FUND L P
4 Oct 23
4
Harry Simeonidis
5 Sep 23
4
Spiro Kevin Sakiris
11 Jul 23
3
Initial statement of insider ownership
1 Jun 23
3
Initial statement of insider ownership
1 Jun 23
SC 13D
Gary W. Rollins Foundation
1 Jun 23
SC 13G
Ionic Ventures, LLC
13 Mar 23
SC 13G
Lind Global Fund II LP
10 Mar 23
4
Spiro Kevin Sakiris
23 Dec 22
3
DAVID A JENKINS
17 Oct 22
3
Jason Isenberg
14 Oct 22
4
Harry Simeonidis
12 Oct 22
4
Jonathan Scott Hurd
12 Oct 22
4
CHRISTOPHER TOWERS
12 Oct 22
4
George Margelis
12 Oct 22
4
LAWRENCE B FISHER
12 Oct 22
4
Steven Constantine Boyages
12 Oct 22
4
Spiro Kevin Sakiris
12 Oct 22
4
Spiro Kevin Sakiris
24 Jun 22
4
Spiro Kevin Sakiris
22 Jun 22
4
Change in insider ownership
22 Feb 22
4
Change in insider ownership
18 Feb 22
4
Change in insider ownership
17 Feb 22
4
Change in insider ownership
15 Feb 22
4
Change in insider ownership
11 Feb 22
4
Change in insider ownership
10 Feb 22
4
Change in insider ownership
8 Feb 22
4
Change in insider ownership
3 Feb 22
4
Change in insider ownership
1 Feb 22
4
Change in insider ownership
1 Feb 22
4
Tom Parmakellis
3 Jan 22